Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates-Reference-Cited by-同舟云学术

Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates

Published:2023-06-28 Issue:7 Volume:27 Page:1269-1275
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Jones Michael T.¹^ORCID,Dirat Olivier²^ORCID,Conlon David A.³^ORCID,Melucci Charles⁴,Schrier Kate⁵,Raglione Thomas⁶,Zhang Qunying⁷,Bulger Paul G.⁸^ORCID

Affiliation:

1. Pharmaceutical Sciences, Pfizer Inc., 875 Chesterfield Parckway West, Chesterfield, Missouri 63017, United States

2. Regulatory CMC, Pfizer Global Product Development, Sandwich CT13 9NJ, United Kingdom

3. Conlon Pharma Consulting, Easton, Pennsylvania 18045, United States

4. Regulatory CMC, Pfizer Global Product Development, 1 Eastern Point Road, Groton, Connecticut, 06340, United States

5. Chemical Outsourcing, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States

6. Chemical Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States

7. Analytical Research & Development AbbVie Inc., 1 North Waukegan Rd., North Chicago, Illinois 60064, United States

8. Department of Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00140

Reference22 articles.

1. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

2. Antibody–Drug Conjugates—A Tutorial Review

3. Fate of Antibody-Drug Conjugates in Cancer Cells

4. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

5. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices;Organic Process Research & Development;2024-07-30